Trial intelligence / Profile preview

SIB-GBM trial: hypofractionated radiotherapy with simultaneous integrated boost and temozolomide in glioblastoma

2009-018258-43Phase 2Active

Sponsor: Azienda Ospedaliero-Universitaria Careggi
Start: Mar 2010
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by Azienda Ospedaliero-Universitaria Careggi. Primary endpoint: 12-month overall survival. Started Mar 2010; status: active.

Drugs

temozolomide

Conditions

glioblastoma (GBM)

Beyond the preview

Go deeper on 2009-018258-43.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-018258-43.